Gonorrhea Therapeutics Market
Gonorrhea Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029
Analysis of Gonorrhea Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Gonorrhea Therapeutics Market in Numbers:
- The gonorrhea therapeutics market recorded ~3% CAGR during the period, 2014 to 2018. Gonorrhea emerged as a public threat worldwide with increasing prevalence of the antibiotic-resistant strains, which sustained the demand for gonorrhea therapeutics in recent years.
- Revenues from gonorrhea therapeutics around the world is estimated at ~US$ 970 Mn in 2019, and record a 4% Y-o-Y over 2018. The gonorrhea therapeutics industry will remain sustained by inclination of the scientific community toward development of alternative therapies and new antibiotics.
- North America remains the most attractive market for gonorrhea therapeutics, primarily upheld by growing government initiatives to compact antibiotic resistance. The US government has released a plan to ‘Combat Antibiotic-Resistant Bacteria’ (CARB) that holds opportunistic potential for companies with strong regional presence.
- Research on the drug-resistance gonorrhea, which is likely to pave a potential pipeline for future treatment, is likely to favor the gonorrhea therapeutics industry.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Competition Landscape
According to our study, the gonorrhea therapeutics market will remain a fairly fragmented landscape, with a large number of contenders collectively holding relatively greater shares than the frontrunners and competitors in the market. With ~40% market shares, the contenders are competing with product innovations in active therapy areas, targeted drug delivery, and capacity expansion to meet growing demand for therapeutics abreast escalating prevalence of gonorrhea.
Frontrunners in the gonorrhea therapeutics market are focusing more on diagnostic tests and services, and R&D dedicated to biosimilars and generics.
The stakeholders in the gonorrhea therapeutics market are more focused on strengthening their distribution in untapped markets, even as entering into strategic partnerships with local distributors to enhance their supplier force and propel sales.
Growing prevalence of antibiotic-resistant gonorrhea has meant that the need for new drugs is evident, as a significant chunk of the global demographic falls prey to the Neisseria gonorrhea bacteria annually. Although progress in gonorrhea vaccines has slugged in the past, recent advances allude an uptick, with conserved vaccine antigens that stimulate bactericidal antibodies being recognized.
New drug developments and laser-sharp focus on quick approvals will remain key winning imperatives for stakeholders in the gonorrhea therapeutics market, in turn complementing their brand repositioning strategies.
Prospects for the gonorrhea therapeutics market seem bullish, with key players increasingly vying for geographical presence, new drug launches, and stable supply chain logistics.
Key Factors Driving Growth in Gonorrhea Therapeutics Market
- Increasing prevalence of gonorrhea, coupled with the rising public awareness about STDs (Sexually-Transmitted Diseases), and advances in relevant diagnostic methods, are the key growth determinants of the gonorrhea therapeutics market.
- Rising incidence of gonorrhea has led to the advent of new diagnostic tests, such as nucleic acid amplification tests (NAATs), which enable early screening to keep the infection from spreading to the upper genital tract.
- Preference for NAATs over traditional cultures has grown significantly in recent years owing to their improved sensitivity and selectivity for Neisseria gonorrhoeae at rectal and oropharyngeal sites in men. Such increased availability and adoption of testing modalities is driving the demand for gonorrhea therapeutics.
- Low cost of gonorrhea therapeutics continues to favor its market prospects, while stakeholders eye to capitalize on the pricing value of widely used STD drugs, such as Ceftriaxone.
- Rapid improvements in healthcare infrastructure, particularly in developed regions are highly likely to create fresh growth avenues in the form of advanced and more effective drugs, thereby escalating the attractiveness of the gonorrhea therapeutics market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Key Challenges Faced by Stakeholders in Gonorrhea Therapeutics Market
- The advent of new antibiotic-resistant strains continues to impede the prospects of the gonorrhea therapeutics market by making the currently available drugs lose their effectiveness in fighting the bacterium. The insidious nature of gonorrhea, owing to its growing success at evolving to evade the antibiotics prescribed to treat remains a significant pain-point for stakeholders.
- The social stigma surrounding open discussions about STD, particularly in underdeveloped and developing countries has been hampering the true potential of the gonorrhea therapeutics market. Due to poor social acceptance of infection in line with the lack of openness and diverse communication regarding sexuality, the adoption of gonorrhea therapeutics is witnessing a restrictive growth.
Paramount Emphasis on Antibiotic R&D to Favor Gains
Antimicrobial resistance (AMR) has become a rapidly growing global public health threat. With AMR making more than 375 million annual new cases of sexually-transmitted infections (STIs) that are stringent to treat, there has emerged a dire need to tackle this upcoming health crisis.
The bacteria that causes gonorrhea is particularly prone to drug resistance, and is classed as ‘high priority’ for renewed antibiotic R&D by leading health organizations.
Turning into a global public health concern, in line with the high unmet need for gonorrhea treatment, growing prevalence of this infection has propelled organizations to collaborate and develop a novel treatment in this light.
For instance, Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) had collaborated to co-develop a new drug zoliflodacin, specifically to treat drug-resistant gonorrhea, while hoping to provide a solution.
Zoliflodacin is a new and first-in-class oral antibiotic that inhibits DNA synthesis in a different way than currently approved antibiotics. Zoliflodacin has been awarded fast track status by the FDA for development as oral treatment for gonorrhea infections, which is likely to translate into significant gains for the gonorrhea therapeutics market in the years to come.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Gonorrhea Therapeutics Market – Research Methodology
An authentic methodology and holistic approach lay the base of the actionable information mentioned in the report on gonorrhea therapeutics market. The Fact.MR study provides detailed information about the growth forecast of gonorrhea therapeutics market, along with an organized breakdown of the factors shaping the dynamics of the market.
Thorough primary and secondary has been employed to accumulate and present valuable insights into the projection analysis of gonorrhea therapeutics market. The report on gonorrhea therapeutics market has also passed through several validation tunnels to ensure that that insights covered in the report are exclusive and one of its kind.
Gonorrhea Therapeutics Market: Segmentation
-
By Drug Type:
- Macrolide Antibiotics (Azithromycin)
- Third-Generation Cephalosporin
- Cefixime
- Cefotaxime
- Ceftizoxime
- Ceftriaxone
- Cetriaxone
- Tetracycline Antibiotics (Doxycycline)
- Fluoroquinolones Antibiotics (Gemifloxacin)
- Aminoglycoside (Gentamicin)
- Aminocyclitol (Spectinomycin)
-
By Route of Administration:
- Oral
- Intra Muscular
-
By Therapy Type:
- Mono Therapy
- Dual Therapy
-
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Globals Market Demand (in Value US$ Mn) Analysis 2014 to 2018 and Forecast, 2019 to 2029
- 6. Market Background
- 7. Globals Market Analysis 2014 to 2018 and Forecast 2019 to 2029, by Region
- 7.1 North America
- 7.2 Latin America
- 7.3 Europe
- 7.4 Middle East and Africa (MEA)
- 7.5 East Asia
- 7.6 South Asia
- 7.7 Oceania
- 8. Globals Market Analysis 2014 to 2018 and Forecast 2019 to 2029, by Drug Type
- 8.1 Macrolide Antibiotics (Azithromycin)
- 8.2 Third-Generation Cephalosporin
- 8.2.1 Cefixime
- 8.2.2 Cefotaxime
- 8.2.3 Ceftizoxime
- 8.2.4 Ceftriaxone
- 8.2.5 Cetriaxone
- 8.3 Tetracycline Antibiotics (Doxycycline)
- 8.4 Fluoroquinolones Antibiotics (Gemifloxacin)
- 8.5 Aminoglycoside (Gentamicin)
- 8.6 Aminocyclitol (Spectinomycin)
- 9. Globals Market Analysis 2014 to 2018 and Forecast 2019 to 2029, by Therapy Type
- 9.1 Mono Therapy
- 9.2 Dual Therapy
- 10. Globals Market Analysis 2014 to 2018 and Forecast 2019 to 2029, by Route of Administration
- 10.1 Oral
- 10.2 Intra Muscular
- 11. Globals Market Analysis 2014 to 2018 and Forecast 2019 to 2029, by Distribution Channel
- 11.1 Institutional Sales
- 11.1.1 Hospitals
- 11.1.2 Speciality Clinics
- 11.2 Retail Sales
- 11.2.1 Hospital Pharmacy
- 11.2.2 Retail Pharmacy
- 11.2.3 Mail Order Pharmacy
- 11.1 Institutional Sales
- 12. North Americas Market Analysis 2014 to 2018 and Forecast 2018 to 2029
- 13. Latin Americas Market Analysis 2014 to 2018 and Forecast 2019 to 2029
- 14. Europes Market Analysis 2014 to 2018 and Forecast 2019 to 2029
- 15. South Asias Market Analysis 2014 to 2018 and Forecast 2019 to 2029
- 16. East Asias Market Analysis 2014 to 2018 and Forecast 2019 to 2029
- 17. Oceanias Market Analysis 2014 to 2018 and Forecast 2019 to 2029
- 18. Middle East and Africas Market Analysis 2014 to 2018 and Forecast 2019 to 2029
- 19. Competition Analysis
- 19.1 Bayer AG
- 19.2 GlaxoSmithKline Plc.
- 19.3 Pfizer Inc.
- 19.4 Allergan plc
- 19.5 Novartis AG
- 19.6 Sanofi S.A.
- 19.7 Mylan N.V.
- 19.8 Teva Pharmaceutical Industries Ltd.
- 19.9 Baxter International Inc.
- 19.10 Hoffmann-La Roche Ltd.
- 19.11 Merck & Co.
- 20. Forecast Assumptions: Relevance and Impact
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Region
Table 02: Global Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 2.1: Global Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 03: Global Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy Type
Table 04: Global Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 05: Global Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 06: North America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Country
Table 07: North America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 7.1: North America Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 08: North America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 09: North America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 10: North America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 11: Latin America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Country
Table 12: Latin America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 12.1: Latin America Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 13: Latin America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 14: Latin America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 15: Latin America Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 16: Europe Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Country
Table 17: Europe Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 17.1: Europe Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 18: Europe Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 19: Europe Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 20: Europe Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 21: South Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Country
Table 22: South Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 22.1: South Asia Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 23: South Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 24: South Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 25: South Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 26: East Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Country
Table 27: East Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 27.1: East Asia Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 28: East Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 29: East Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 30: East Asia Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 31: Oceania Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Country
Table 32: Oceania Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 32.1: Oceania Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 33: Oceania Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 34: Oceania Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 35: Oceania Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 36: Middle East & Africa Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Country
Table 37: Middle East & Africa Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 37.1: Oceania Market Volume (Tons and Units) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 38: Middle East & Africa Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 39: Middle East & Africa Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 40: Middle East & Africa Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 41: China Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 42: China Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 43: China Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 44: China Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 45: Japan Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 46: Japan Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 47: Japan Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 48: Japan Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
Table 49: India Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Drug Type
Table 50: India Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Therapy
Table 51: India Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Route of Administration
Table 52: India Market Size (US$ Mn) Analysis 2014 to 2018 and Forecast 2019 to 2029, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Globals Market Value Share 2018A, By Drug Type
Figure 02: Globals Market Value Share 2018A, By Therapy
Figure 03: Globals Market Value Share 2018A, By Route of Administration
Figure 04: Globals Market Value Share 2018A, By Distribution Channel
Figure 05: Global Market Value Analysis and Forecast, 2017 to 2029 (US$ Mn)
Figure 06: Global Market Value Opportunity Assessment, 2019 to 2029
Figure 07: Global Revenue Share by Region, 2019E and 2029F
Figure 08: Global Market Attractiveness Analysis, By Region, 2019E
Figure 09: Global Revenue Share (in US$ Mn) by Drug Type, 2019E and 2029F
Figure 10: Global Market Attractiveness Analysis, By Drug Type, 2019E
Figure 11: Global Revenue Share by Therapy Type, 2019E and 2029F
Figure 12: Global Market Attractiveness Analysis, By Therapy Type, 2019E
Figure 13: Global Revenue Share by Route of Administration, 2019E and 2029F
Figure 14: Global Market Attractiveness Analysis, By Route of Administration, 2019E
Figure 15: Global Revenue Share by Distribution Channel, 2019E and 2029F
Figure 16: Global Market Attractiveness Analysis, By Distribution Channel, 2019E
Figure 17: North Americas Market Value Share 2019E, By Drug Type
Figure 18: North Americas Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 19: North Americas Market Value Share 2019E, By Therapy
Figure 20: North Americas Market Value Share 2019E, By Route of Administration
Figure 21: North Americas Market Value Share 2019E, By Distribution Channel
Figure 22: North Americas Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 23: North Americas Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 24: North America Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 25: North America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 26: North America Market Attractiveness Analysis, By Country
Figure 27: North America Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 28: North America Market Attractiveness Analysis, By Country
Figure 29: North America Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 30: North America Market Attractiveness Analysis, By Therapy
Figure 31: North America Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 32: North America Market Attractiveness Analysis, By Route of Administration
Figure 33: North America Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 34: North America Market Attractiveness Analysis, By Distribution Channel
Figure 35: North America Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 36: Latin Americas Market Value Share 2019E, By Drug Type
Figure 37: Latin Americas Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 38: Latin Americas Market Value Share 2019E, By Therapy
Figure 39: Latin Americas Market Value Share 2019E, By Route of Administration
Figure 40: Latin Americas Market Value Share 2019E, By Distribution Channel
Figure 41: Latin Americas Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 42: Latin Americas Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 43: Latin America Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 44: Latin America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 45: Latin America Market Attractiveness Analysis, By Country
Figure 46: Latin America Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 47: Latin America Market Attractiveness Analysis, By Drug Type
Figure 48: Latin America Market Value Share Analysis, By Region, 2018 & 2029, By Drug Type
Figure 49: Latin America Market Attractiveness Analysis, By Therapy
Figure 50: Latin America Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 51: Latin America Market Attractiveness Analysis, By Route of Administration
Figure 52: Latin America Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 53: Latin America Market Attractiveness Analysis, By Distribution Channel
Figure 54: Latin America Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 55: Europes Market Value Share 2019E, By Drug Type
Figure 56: Europes Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 57: Europes Market Value Share 2019E, By Therapy
Figure 58: Europes Market Value Share 2019E, By Route of Administration
Figure 59: Europes Market Value Share 2019E, By Distribution Channel
Figure 60: Europes Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 61: Europes Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 62: Europe Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 63: Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 64: Europe Market Attractiveness Analysis, By Country
Figure 65: Europe Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 66: Europe Market Attractiveness Analysis, By Drug Type
Figure 67: Europe Market Value Share Analysis, By Region, 2018 & 2029, By Drug Type
Figure 68: Europe Market Attractiveness Analysis, By Therapy
Figure 69: Europe Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 70: Europe Market Attractiveness Analysis, By Route of Administration
Figure 71: Europe Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 72: Europe Market Attractiveness Analysis, By Distribution Channel
Figure 73: Europe Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 74: South Asias Market Value Share 2019E, By Drug Type
Figure 75: South Asias Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 76: South Asias Market Value Share 2019E, By Therapy
Figure 77: South Asias Market Value Share 2019E, By Route of Administration
Figure 78: South Asias Market Value Share 2019E, By Distribution Channel
Figure 79: South Asias Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 80: South Asias Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 81: South Asia Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 82: South Asia Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 83: South Asia Market Attractiveness Analysis, By Country
Figure 84: South Asia Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 85: South Asia Market Attractiveness Analysis, By Drug Type
Figure 86: South Asia Market Value Share Analysis, By Region, 2018 & 2029, By Drug Type
Figure 87: South Asia Market Attractiveness Analysis, By Therapy
Figure 88: South Asia Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 89: South Asia Market Attractiveness Analysis, By Route of Administration
Figure 90: South Asia Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 91: South Asia Market Attractiveness Analysis, By Distribution Channel
Figure 92: South Asia Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 93: East Asias Market Value Share 2019E, By Drug Type
Figure 94: East Asias Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 95: East Asias Market Value Share 2019E, By Therapy
Figure 96: East Asias Market Value Share 2019E, By Route of Administration
Figure 97: East Asias Market Value Share 2019E, By Distribution Channel
Figure 98: East Asias Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 99: East Asias Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 100: East Asia Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 101: East Asia Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 102: East Asia Market Attractiveness Analysis, By Country
Figure 103: East Asia Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 104: East Asia Market Attractiveness Analysis, By Drug Type
Figure 105: East Asia Market Value Share Analysis, By Region, 2018 & 2029, By Drug Type
Figure 106: East Asia Market Attractiveness Analysis, By Therapy
Figure 107: East Asia Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 108: East Asia Market Attractiveness Analysis, By Route of Administration
Figure 109: East Asia Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 110: East Asia Market Attractiveness Analysis, By Distribution Channel
Figure 111: East Asia Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 112: Oceanias Market Value Share 2019E, By Drug Type
Figure 113: Oceanias Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 114: Oceanias Market Value Share 2019E, By Therapy
Figure 115: Oceanias Market Value Share 2019E, By Route of Administration
Figure 116: Oceanias Market Value Share 2019E, By Distribution Channel
Figure 117: Oceanias Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 118: Oceanias Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 119: Oceania Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 120: Oceania Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 121: Oceania Market Attractiveness Analysis, By Country
Figure 122: Oceania Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 123: Oceania Market Attractiveness Analysis, By Drug Type
Figure 124: Oceania Market Value Share Analysis, By Region, 2018 & 2029, By Drug Type
Figure 125: Oceania Market Attractiveness Analysis, By Therapy
Figure 126: Oceania Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 127: Oceania Market Attractiveness Analysis, By Route of Administration
Figure 128: Oceania Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 129: Oceania Market Attractiveness Analysis, By Distribution Channel
Figure 130: Oceania Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 131: Middle East & Africas Market Value Share 2019E, By Drug Type
Figure 132: Middle East & Africas Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 133: Middle East & Africas Market Value Share 2019E, By Therapy
Figure 134: Middle East & Africas Market Value Share 2019E, By Route of Administration
Figure 135: Middle East & Africas Market Value Share 2019E, By Distribution Channel
Figure 136: Middle East & Africas Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 137: Middle East & Africas Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 138: Middle East & Africa Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 139: Middle East & Africa Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 140: Middle East & Africa Market Attractiveness Analysis, By Country
Figure 141: Middle East & Africa Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 142: Middle East & Africa Market Attractiveness Analysis, By Drug Type
Figure 143: Middle East & Africa Market Value Share Analysis, By Region, 2018 & 2029, By Drug Type
Figure 144: Middle East & Africa Market Attractiveness Analysis, By Therapy
Figure 145: Middle East & Africa Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 146: Middle East & Africa Market Attractiveness Analysis, By Route of Administration
Figure 147: Middle East & Africa Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 148: Middle East & Africa Market Attractiveness Analysis, By Distribution Channel
Figure 149: Middle East & Africa Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 150: Emerging Countries Market Value Share (2019E)
Figure 151: Emerging Countries Market Value (US$ Mn), By Key Countries, 2014A to 2029E
Figure 152: Chinas Market Value Share 2019E, By Drug Type
Figure 153: Chinas Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 154: Chinas Market Value Share 2019E, By Therapy
Figure 155: Chinas Market Value Share 2019E, By Route of Administration
Figure 156: Chinas Market Value Share 2019E, By Distribution Channel
Figure 157: Chinas Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 158: Chinas Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 159: China Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 160: China Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 161: China Market Attractiveness Analysis, By Country
Figure 162: China Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 163: China Market Attractiveness Analysis, By Therapy
Figure 164: China Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 165: China Market Attractiveness Analysis, By Route of Administration
Figure 166: China Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 167: China Market Attractiveness Analysis, By Distribution Channel
Figure 168: China Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 169: Japans Market Value Share 2019E, By Drug Type
Figure 170: Japans Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 171: Japans Market Value Share 2019E, By Therapy
Figure 172: Japans Market Value Share 2019E, By Route of Administration
Figure 173: Japans Market Value Share 2019E, By Distribution Channel
Figure 174: Japans Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 175: Japans Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 176: Japan Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 177: Japan Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 178: Japan Market Attractiveness Analysis, By Country
Figure 179: Japan Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 180: Japan Market Attractiveness Analysis, By Therapy
Figure 181: Japan Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 182: Japan Market Attractiveness Analysis, By Route of Administration
Figure 183: Japan Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 184: Japan Market Attractiveness Analysis, By Distribution Channel
Figure 185: Japan Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Figure 186: Indias Market Value Share 2019E, By Drug Type
Figure 187: Indias Market Value Share 2019E, By Drug Type (3rd Generation Cephalosporin)
Figure 188: Indias Market Value Share 2019E, By Therapy
Figure 189: Indias Market Value Share 2019E, By Route of Administration
Figure 190: Indias Market Value Share 2019E, By Distribution Channel
Figure 191: Indias Market Value Share 2019E, By Distribution Channel (Institutional Sales)
Figure 192: Indias Market Value Share 2019E, By Distribution Channel (Retail Sales)
Figure 193: India Market Size (US$ Mn) Analysis, 2014 to 2018
Figure 194: India Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019 to 2029
Figure 195: India Market Attractiveness Analysis, By Country
Figure 196: India Market Value Share Analysis, By Region, 2018 & 2029, By Country
Figure 197: India Market Attractiveness Analysis, By Therapy
Figure 198: India Market Value Share Analysis, By Region, 2018 & 2029, By Therapy
Figure 199: India Market Attractiveness Analysis, By Route of Administration
Figure 200: India Market Value Share Analysis, By Region, 2018 & 2029, By Route of Administration
Figure 201: India Market Attractiveness Analysis, By Distribution Channel
Figure 202: India Market Value Share Analysis, By Region, 2018 & 2029, By Distribution Channel
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the global Gonorrhea Therapeutics Market worth?
Revenues from gonorrhea therapeutics around the world is estimated at ~US$ 970 Mn in 2019, and record a 4% Y-o-Y over 2018.
What are the key markets for Gonorrhea Therapeutics Market?
North America, East Asia are the key markets for Gonorrhea Therapeutics Market
Gonorrhea Therapeutics Market